Caracterización de los pacientes con sospecha de aspergilosis invasiva estudiados con prueba Platelia Aspergillus®
Barra lateral del artículo
Descargas
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Contenido principal del artículo
Resumen
Objetivo: describir las características de los pacientes en los que se realizó prueba Platelia Aspergillus® por sospecha de AI, y los resultados de la prueba según las categorías diagnósticas.
Metodología: se revisaron retrospectivamente las historias clínicas de pacientes con sospecha de AI atendidos en instituciones de salud de Medellín a quienes se les realizó la prueba Platelia Aspergillus®. Se colectaron y analizaron de manera descriptiva los datos clínicos, imaginológicos, microbiológicos y los resultados de la prueba Platelia Aspergillus®.
Resultados: se incluyeron 78 pacientes atendidos entre 2006- 2008. Se diagnosticó AI en 21 (26.9%) pacientes, colonización en ocho (10.3%) pacientes. La forma pulmonar invasiva aguda se encontró en 17 (81.0%), forma diseminada en tres (14.3%). La fiebre y la disnea fueron la principal manifestación. En la tomografía de pulmón se observaron más frecuentemente nódulos pulmonares. La prueba fue positiva en 31 (39.7%) pacientes, en 50% de los pacientes colonizados. En 17 (47.2%) de los 36 pacientes recibieron antibióticos betalactámicos, la prueba fue positivo.
Conclusiones: la AI puede encontrarse hasta en la tercera parte de pacientes con sospecha clínica; sin embargo, el diagnóstico es difícil debido al cuadro clínico inespecífico, además de las dificultades para obtener muestras clínicas y al pobre rendimiento de las pruebas diagnósticas.
Citas
Morgan J, Wannemuehler KA, Marr KA, Hadley S, Kontoyiannis DP, Walsh TJ, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol. 2005 May; 43 Suppl 1:S49-58.
Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008 Feb 1;46(3):327-60.
Bergeron A, Belle A, Sulahian A, Lacroix C, Chevret S, Raffoux E, et al. Contribution of galactomannan antigen detection in BAL to the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. Chest. 2010 Feb; 137(2):410-5.
De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008 Jun 15; 46(12):1813-21.
Herbrecht R, Letscher-Bru V, Oprea C, Lioure B, Waller J, Campos F, et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol. 2002 Apr 1; 20(7):1898- 906.
Maertens J, Theunissen K, Verbeken E, Lagrou K, Verhaegen J, Boogaerts M, et al. Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol. 2004 Sep; 126(6):852-60.
Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis. 2004 Jun; 4(6):349-57.
Quindós G. New microbiological techniques for the diagnosis of invasive mycoses caused by filamentous fungi. Clin Microbiol Infect. 2006; 12(Suppl 7):40-52.
Wheat LJ, Walsh TJ. Diagnosis of invasive aspergillosis by galactomannan antigenemia detection using an enzyme immunoassay. Eur J Clin Microbiol Infect Dis. 2008 Apr; 27(4):245-51.
Koch S, Hohne FM, Tietz HJ. Incidence of systemic mycoses in autopsy material. Mycoses. 2004 Feb; 47 (1-2):40-6.
Lass-Florl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses. 2009 May; 52(3):197-205.
Denning DW. Early diagnosis of invasive aspergillosis. Lancet. 2000 Feb 5; 355(9202):423-4.
Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine. 2000 Jul; 79(4):250-60.
Denning DW. Invasive aspergillosis. Clin Infect Dis. 1998 Apr; 26(4):781-803; quiz 4-5.
Mikulska M, Raiola AM, Bruno B, Furfaro E, Van Lint MT, Bregante S, et al. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transplant. 2009 Sep; 44(6):361-70.
Husain S. Unique characteristics of fungal infections in lung transplant recipients.Clin Chest Med. 2009 Jun; 30(2):307-13.
Rosenhagen M, Feldhues R, Schmidt J, Hoppe-Tichy T, Geiss HK. A risk profile for invasive aspergillosis in liver transplant recipients. Infection. 2009 Aug; 37(4):313-9.
Judson MA. Allergic bronchopulmonary aspergillosis after infliximab therapy for sarcoidosis: a potential mechanism related to T-helper cytokine balance. Chest. 2009 May; 135(5):1358-9.
Nedel WL, Kontoyiannis DP, Pasqualotto AC. Aspergillosis in patients treated with monoclonal antibodies. Rev Iberoam Micol. 2009 Sep 30; 26(3):175-83.
Segal BH. Aspergillosis. N Engl J Med. 2009 Apr 30; 360(18):1870-84.
Riscili BP, Wood KL. Noninvasive pulmonary Aspergillus infections. Clin Chest Med. 2009 Jun; 30(2):315-35.
Vonberg RP, Gastmeier P. Nosocomial aspergillosis in outbreak settings. J Hosp Infect. 2006 Jul; 63(3):246- 54.
Sivak-Callcott JA, Livesley N, Nugent RA, Rasmussen SL, Saeed P, Rootman J. Localised invasive sino-orbital aspergillosis: characteristic features. Br J Ophthalmol. 2004 May; 88(5):681-7.
Clancy CJ, Nguyen MH. Invasive sinus aspergillosis in apparently immunocompetent hosts. J Infect. 1998 Nov; 37(3):229-40.
Onozawa M, Takahashi S, Kanamori H, Kahata K, Kondo T, Hashino S, et al. Pseudomembranous tracheobronchial aspergillosis. Intern Med J. 2009 Jan; 39(1):65-6.
Routsi C, Kaltsas P, Bessis E, Rontogianni D, Kollias S, Roussos C. Airway obstruction and acute respiratory failure due to Aspergillus tracheobronchitis. Crit Care Med. 2004 Feb; 32(2):580-2.
Angelotti T, Krishna G, Scott J, Berry G, Weinacker A. Nodular invasive tracheobronchitis due to Aspergillus in a patient with systemic lupus erythematosus. Lupus. 2002; 11(5):325-8.
Lambertucci JR, Fonseca P, Linares DB. Invasive aspergillosis of the orbit and cavernous sinus in a patient with Aids. . Rev Soc Bras Med Trop. 2009 Dec; 42(6):734-5.
Gupta A, Khaira A, Lata S, Sharma A, Tiwari SC. Primary cutaneous aspergillosis in renal transplant recipient. Saudi J Kidney Dis Transpl. 2009 Sep; 20(5):848-9.
Siddiqui AA, Shah AA, Bashir SH. Craniocerebral aspergillosis of sinonasal origin in immunocompetent patients: clinical spectrum and outcome in 25 cases. Neurosurgery. 2004 Sep; 55(3):602-11; discussion 11-3.
Almutairi BM, Nguyen TB, Jansen GH, Asseri AH. Invasive aspergillosis of the brain: radiologicpathologic correlation. Radiographics. 2009 Mar-Apr; 29(2):375-9.
Sutton DA, Wickes BL, Romanelli AM, Rinaldi MG, Thompson EH, Fothergill AW, et al. Cerebral aspergillosis caused by Aspergillus granulosus. J Clin Microbiol. 2009 Oct; 47(10):3386-90.
Maertens J, Theunissen K, Lodewyck T, Lagrou K, Van Eldere J. Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders. Mycoses. 2007; 50 Suppl 1:2-17.
Petraitiene R, Petraitis V, Groll AH, Sein T, Piscitelli S, Candelario M, et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother. 2001 Mar; 45(3):857-69.
Greene RE, Schlamm HT, Oestmann JW, Stark P, Durand C, Lortholary O, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis. 2007 Feb 1; 44(3):373-9.
Weisser M, Rausch C, Droll A, Simcock M, Sendi P, Steffen I, et al. Galactomannan does not precede major signs on a pulmonary computerized tomographic scan suggestive of invasive aspergillosis in patients with hematological malignancies. Clin Infect Dis. 2005 Oct 15; 41(8):1143-9.
Walsh TJ, Petraitis V, Petraitiene R, Solomon J, Bacher JD, Greene L, et al. Diagnostic imaging of experimental invasive pulmonary aspergillosis. Med Mycol. 2009; 47 Suppl 1:S138-45.
Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002 Aug 8; 347(6):408- 15.
Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis.2004 Aug 1; 190(3):641-9.